Auto-Tuning Drug Regulator Construct, US20260108617A1
Summary
USPTO published patent application US20260108617A1 for an auto-tuning drug regulator construct with a filing date of January 17, 2024. The invention describes a chemical construct comprising a biorecognition component, an incapacitation component, and an active drug component, where drug release is triggered by the presence or absence of a target enzyme. Six inventors are named: Tapash Jay Sarkar, Edward Njoo, Lorelei Xia, Akira Yamamoto, Zachary Bashkin, and Warren Chang. This document is a publication announcement only and creates no compliance obligations.
“The construct is a chemical structure comprising: (a) a biorecognition component comprising a substrate recognized by an enzyme, (b) an incapacitation component, and (c) an active drug component.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108617A1 for an auto-tuning drug regulator construct, classified under CPC A61K 47/65. The application claims a chemical structure with three integrated components: a biorecognition component recognized by a target enzyme, an incapacitation component that renders the drug benign upon substrate-enzyme interaction, and an active drug component that takes effect when the enzyme is inactive or absent.
Pharmaceutical and biotechnology companies developing enzyme-responsive drug delivery systems should note this filing as it may represent prior art for similar approaches. Patent applicants in this space should conduct clearance searches against the claims. No regulatory obligations or compliance deadlines arise from this publication.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS
Application US20260108617A1 Kind: A1 Apr 23, 2026
Inventors
Tapash Jay SARKAR, Edward NJOO, Lorelei XIA, Akira YAMAMOTO, Zachary BASHKIN, Warren CHANG
Abstract
The present invention provides a regulator construct in which the drug efficacy is auto-regulated by the presence of a indicator enzyme. The construct is a chemical structure comprising: (a) a biorecognition component comprising a substrate recognized by an enzyme, (b) an incapacitation component, and (c) an active drug component. The incapacitation component provides a chemical incapacitation mechanism to render benign or incapacitate the drug component, after the substrate-enzyme interaction, allowing additionally for the creation of altered benign chemical structures while, otherwise, when said enzymes is inactive or absent the drug will take effect.
CPC Classifications
A61K 47/65
Filing Date
2024-01-17
Application No.
19148655
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.